https://www.selleckchem.com/pr....oducts/netarsudil-ar
The aim of this study was to evaluate post-percutaneous coronary intervention (PCI) outcomes in relation to pre-procedural glycated hemoglobin (HbA ) levels from a large, contemporary cohort. There are limited data evaluating associations between HbA , a marker of glycemic control, and ischemic risk following PCI. All patients with known HbA levels undergoing PCI at a single institution between 2009 and 2017 were included. Patients were divided into 5 groups on the basis of HbA level≤5.5%, 5.6% to 6.0%, 6.1% to 7.0%, 7.1% to
Curtir
Comentario
Compartilhar
